New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
12:06 EDTNVS, SFLY, BPI, BBEP, CHRWHigh option volume stocks: BBEP SFLY CHRW BPI NVS
News For BBEP;SFLY;CHRW;BPI;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
10:00 EDTSFLYOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Altria Group (MO) downgraded to Outperform from Buy at CLSA... Baxter (BAX) downgraded to Market Perform from Outperform at Leerink... Changyou.com (CYOU) downgraded to Hold from Buy at Summit Research... Depomed (DEPO) downgraded to Neutral from Buy at Janney Capital... Euronet (EEFT) downgraded to Neutral from Buy at Monness Crespi... Foundation Medicine (FMI) downgraded to Market Perform at JMP Securities... Garmin (GRMN) downgraded to Underweight from Neutral at JPMorgan... Golden Star Resources (GSS) downgraded to Hold at Canaccord... Grainger (GWW) downgraded on negative catalysts at RBC Capital... Henry Schein (HSIC) downgraded to Hold from Buy at Evercore ISI... LINN Energy (LINE) downgraded to Market Perform from Outperform at Raymond James... LifeLock (LOCK) downgraded to Neutral from Buy at BofA/Merrill... LinnCo (LNCO) downgraded to Market Perform from Outperform at Raymond James... Manitowoc (MTW) downgraded to Hold from Buy at BB&T... PACCAR (PCAR) downgraded to Equal Weight on peak cycle concerns at Morgan Stanley... PG&E (PCG) downgraded to Neutral from Outperform at Credit Suisse... Pacer (PACR) downgraded to Equal Weight from Overweight at Morgan Stanley... Penn Virginia (PVA) downgraded to Sector Perform from Outperform at Scotia... Shutterfly (SFLY) downgraded to Market Perform at Raymond James... Terex (TEX) downgraded to Hold from Buy at BB&T... Total System (TSS) downgraded to Neutral at Baird... Whiting Petroleum (WLL) downgraded to Equal Weight from Overweight at Stephens... Whole Foods (WFM) downgraded to Equal Weight from Overweight at Morgan Stanley.
08:37 EDTSFLYShutterfly downgraded to Market Perform at Raymond James
Subscribe for More Information
06:29 EDTSFLYShutterfly downgraded to Market Perform from Outperform at Raymond James
July 29, 2015
16:37 EDTSFLYShutterfly sees FY15 EPS (32c)-(13c), consensus (33c)
Subscribe for More Information
16:35 EDTSFLYShutterfly sees Q3 EPS ($1.47)-($1.32), consensus ($1.34)
Subscribe for More Information
16:33 EDTSFLYShutterfly reports Q2 GAAP EPS (63c),may not compare to consensus ($1.05)
Subscribe for More Information
07:17 EDTSFLYShutterfly volatility increases into Q2 and outlook
Shutterfly August call option implied volatility is at 43, September is at 35; compared to its 52-week range of 24 to 48, suggesting large near term price movement into the expected release of Q2 results today.
05:28 EDTNVSNovartis announces equity stake in Mereo BioPharma Group
Novartis announced a swap of clinical assets for equity with Mereo BioPharma Group. The deal involves compounds in areas of unmet medical need including BPS-804, to improve bone density in brittle bone syndrome, an orphan disease; BCT-197 for acute exacerbations in COPD, and BGS-649 for obese men with hypogonadotrophic hypogonadism to normalize testosterone levels. Under the terms of the agreement, Novartis will have an equity stake in Mereo and will share in the success of the development of these compounds, including a share on milestones and royalties on future commercial sales.
July 28, 2015
16:33 EDTCHRWC.H. Robinson reports Q2 EPS 94c, consensus 86c
Reports Q2 revenue $3.55B, consensus $3.69B.
15:21 EDTCHRWNotable companies reporting after market close
Subscribe for More Information
July 24, 2015
10:56 EDTNVSNovartis announces FDA approval of Odomzo
Subscribe for More Information
09:02 EDTNVSLigand says Revolade recommended by CHMP for EU approval for SAA
Subscribe for More Information
08:30 EDTSFLYShutterfly July weekly volatility elevated into Q2 and outlook
Shutterfly August call option implied volatility is at 39, September is at 30; compared to its 52-week range of 24 to 48, suggesting large near term price movement into the expected release of Q2 results on July 29.
07:17 EDTNVSNovartis combination therapy Tafinlar, Mekinist achieves regulatory milestones
Subscribe for More Information
July 22, 2015
07:03 EDTNVSIgnyta names Bernard Parker as Chief Commercial Officer
Subscribe for More Information
July 21, 2015
11:49 EDTNVSNovartis may sell Amgen's cancer drug as soon as September, Bloomberg says
Subscribe for More Information
05:20 EDTNVSNovartis backs FY15 revenue guidance of up mid-single digit
Subscribe for More Information
05:17 EDTNVSNovartis reports Q2 core EPS $1.27, consensus $1.24
Reports Q2 revenue $12.7B, consensus $12.44B. Further strengthening of USD impacted sales by -11% and core operating income by -13%. Growth Products, an indicator of the rejuvenation of the portfolio, contributed 35% of continuing operations net sales in Q2, and were up 24%. In Pharmaceuticals, Growth Products contributed 44% of division net sales in the quarter, and sales for these products were up 38%.
July 20, 2015
08:25 EDTNVSNovartis management to meet with JPMorgan
Subscribe for More Information
07:32 EDTNVSAlzheimer's Association to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use